Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Glaxo to pay $750 million penalty

By Ben Rooney, staff reporter

NEW YORK (CNNMoney.com) -- SB Pharmaco, a unit of health care giant GlaxoSmithKline, pleaded guilty to charges it sold "adulterated" drugs made at a now-closed plant in Puerto Rico, federal regulators said Tuesday.

Glaxo will pay a criminal fine of $150 million and civil penalties totaling $600 million to federal and state authorities, the U.S. Justice Department said.

SB Pharmaco manufactured and distributed drugs that did not conform to current "good manufacturing" practices, according to prosecutors. Under federal law, drugmakers are required to meet certain standards designed to ensure the safety and purity of drugs sold in the United States.

The drugs, made at a Glaxo facility in Cidra, Puerto Rico between 2001 and 2005, are Kytril, Bactroban, Paxil CR and Avandamet. They are used to treat infection, nausea, depression and Type II diabetes.

In addition, prosecutors said Glaxo knowingly made false claims to federal health care programs such as Medicaid regarding the drugs in question.

Glaxo (GSK) reported a $750 million charge in its second-quarter financial statement in July, after the company came to a tentative agreement to settle the charges with regulators. The company said it expects no additional financial impact from the penalties.

U.S. depository shares of the U.K.-based company fell 0.4% to $40.16 on the New York Stock Exchange.

PD Villarreal, head of global litigation at Glaxo, said the fines resolve "a significant and long-standing legal issue," adding that the company regrets failing to meet U.S. safety standards.

"GSK worked hard to resolve fully the manufacturing issues at the Cidra facility prior to its closure in 2009 and we are committed to continuous improvement in our manufacturing processes," Villarreal said in a statement.

Meanwhile, prosecutors said the case sends a message to the pharmaceutical industry that lapses in quality control will not be tolerated.

"The industry has an obligation to ensure that all rules, regulations and laws are complied with," said U.S. Attorney Carmen Ortiz. "To do less erodes public confidence and compromises patient safety."

The whistle blower in the civil case, Cheryl Eckard, will be awarded about $96 million of the fines that Glaxo will pay to the federal government. To top of page

Index Last Change % Change
Dow 17,050.75 138.46 0.82%
Nasdaq 4,810.79 19.64 0.41%
S&P 500 2,013.43 17.60 0.88%
Treasuries 2.11 0.05 2.23%
Data as of 8:09pm ET
Company Price Change % Change
Bank of America Corp... 15.75 0.00 0.00%
EMC Corp 27.18 1.22 4.70%
Apple Inc 109.50 -1.28 -1.16%
Freeport-McMoRan Inc... 13.46 0.45 3.46%
General Electric Co 28.03 0.26 0.94%
Data as of 4:03pm ET


Judge denies request by Paul Smith's College to change its name in order to secure huge donation from philanthropist Joan Weill? More

The National Domestic Workers Alliance introduced a new initiative, Good Work Code, to set standards and protections for on-demand workers. More

The National Domestic Workers Alliance introduced a new initiative, Good Work Code, to set standards and protections for on-demand workers. More

Karim Abouelnaga turned down a job on Wall Street to address a problem that set him back as a low-income student: the summer slide. More

One of the largest pension funds in the country says it needs to cut benefits for 273,000 current and future retirees as soon as July. Otherwise, it won't be able to pay any benefits after 2025. More